Increased plasmablasts enhance T cell-mediated beta cell destruction and promote the development of type 1 diabetes

Qing Ling1†, Lei Shen2†, Wei Zhang1, DuoDuo Qu1, Hongdong Wang1, Bin Wang3, Yong Liu4, Jing Lu1*, Dalong Zhu1* and Yan Bi1*

Abstract

**Background:** Although type 1 diabetes (T1D) is typically described as a T cell-mediated autoimmune disease, increasing evidence for a role of B cells has emerged. However, the pivotal disease-relevant B cell subset and its contribution to islet autoimmunity remain elusive.

**Methods:** The frequencies and phenotypic characteristics of circulating B cell subsets were analyzed using flow cytometry in individuals with new-onset T1D, long-term T1D, type 2 diabetes, and nondiabetic controls, and also in a prospective cohort of patients receiving mesenchymal stromal cell (MSC) transplantation. NOD mice and adoptive transfer assay were used to dissect the role of the certain B cell subset in disease progression. An in-vitro coculture system of islets with immune cells was established to examine the response against islets and the underlying mechanisms.

**Results:** We identified that plasmablasts, a B cell subset at the antibody-secreting stage, were significantly increased and correlated with the deterioration of beta cell function in patients with new-onset T1D. Further, a fall of plasmablast number was associated with the preservation of beta cell function in patients who received MSC transplantation after 3 months of follow-up. Meanwhile, a gradual increase of plasmablasts in pancreatic lymph nodes during the natural progression of insulitis was observed in non-obese diabetic (NOD) mice; adoptive transfer of plasmablasts together with T cells from NOD mice accelerated diabetes onset in NOD/SCID recipients.

**Conclusions:** Our study revealed that plasmablasts may function as antigen-presenting cells and promote the activation and proinflammatory response of CD4+ T cells, further contributing to the T cell-mediated beta cell destruction. Our results provide insights into the pathogenic role of plasmablasts in islet autoimmunity and may offer new translational strategies for inhibiting T1D development.

**Keywords:** Autoimmunity, B cell subset, Plasmablast, T cell, Type 1 diabetes

Background

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the progressive deterioration of pancreatic beta cell function, insulin deficiency, and hyperglycemia (Barnett 2018). The pathogenesis of T1D involves islet infiltration by various components of immune...
systems (insulitis), which results in ongoing islet autoimmunity and destruction of beta cells. Although autoreactive CD8+ T cells and CD4+ T cells are classically considered as the primary effectors mediating beta cell damage, other immune cells are also crucial for disease development (Boldison and Wong 2016).

B cells are typically considered as the main source of autoantibodies against specific beta cell proteins of glutamate decarboxylase (GADA), tyrosine phosphatase (IA2A), and zinc transporter 8 et al., which serve as hallmarks of T1D onset (Ling et al. 2018; Lampasona and Liberati 2016). However, emerging evidence also indicates an active role of B cells directly involved in beta cell destruction. Studies have demonstrated that B cells are required for the development of diabetes in non-obese diabetic (NOD) mice, which can be prevented by B cell depletion (Smith et al. 2017; Hu et al. 2007; Serreze et al. 1996; Falcone et al. 1998). B cell depletion therapy with an anti-CD20 antibody in new-onset patients with T1D showed efficacy in preserving beta cell function for 1 year; whereas such therapy showed limited effect after 2 years (Pescovitz et al. 2014; Pescovitz et al. 2009). Thereafter, little progress has been made until recently, studies of human pancreas from T1D donors draw attention to the role of B cells in islet autoimmunity (Wang et al. 2019; Damond et al. 2019; Leete et al. 2016). B cells were especially enriched in the proximal region of islets with remnant beta cells, which were linked to a rapid beta cell loss in young patients (Wang et al. 2019; Leete et al. 2016). Meanwhile, increasing studies begin to focus on abnormalities of certain B cell subsets. Decreased regulatory B cells and intolerance of antigen-specific B cells have been reported to participate in T1D progression (Smith et al. 2018; Smith et al. 2015; Kleffel et al. 2015). Hence, an in-depth analysis of B cell subsets in T1D progression is important for understanding the disease pathogenesis and determining optimal immunotherapies.

Up to now, only a few studies have examined the profile of B cell subpopulations in T1D; moreover, such studies apply distinct strategies for cell detection. One study analyzed B cell subsets based on their localization in second lymphoid tissues (Deng et al. 2016). Other studies stratified peripheral B cells as naive, unswitched memory B cells, switched memory B cells, plasmablasts, and plasma cells, representing different stages during differentiation (Parackova et al. 2017; Hanley, et al. 2017; Thompson et al. 2014; Viisanan et al. 2017; Yang et al. 2019). Nevertheless, these studies fail to provide consistent results on the alteration of B cell subsets. Furthermore, the mechanisms underlying altered B cell subsets and their role in promoting T1D progression still remain elusive. Therefore, more efforts are required to clarify the pivotal disease-relevant B cell subset and its associated mechanisms contributing to T1D pathogenesis.

In this study, we focused on characterizing the major altered B cell subset associated with the development of T1D. By analyzing alterations in circulating B cell subsets from patients with T1D, we found plasmablasts were obviously elevated and associated with the deterioration of beta cell function. Moreover, in our recently published immunotherapy using mesenchymal stromal cells (MSC) in patients with T1D, clinical remission characterized by improved beta cell function was significantly improved after MSC transplantation. By analyzing the change of plasmablasts in recipients during MSC therapy, the association between decreased plasmablasts and preservation of beta cell function was demonstrated. The characterization and pathological effects of plasmablasts were further investigated in NOD mice which highlight their key role in the autoimmune response to pancreatic beta cells.

Materials and methods

Participants

Cross-sectional cohorts of 36 patients with new-onset T1D, 20 with long-term T1D, 22 with new-onset type 2 diabetes, and 26 sex-matched nondiabetic control subjects were recruited during 2017–2019 at the Endocrinology Department of Affiliated Drum Tower Hospital, Medical School of Nanjing University. Diabetes was diagnosed according to American Diabetes Association criteria (American Diabetes Association 2020). Patients with T1D were positive for at least one islet autoantibody and/or a fasting C-peptide ≤ 200 pmol/L. Time from diagnosis was categorized as < 1 year for new-onset and ≥ 1 year for long-term diabetes. The sex-matched type 2 diabetes patients were recently diagnosed and were seronegative for islet autoantibodies. The control individuals were euglycemia and without islet autoantibodies. Exclusion criteria were: malignancy; allergic state; acute infection in the past 3 months; other autoimmune diseases, e.g., rheumatoid arthritis and systemic lupus erythematosus; pregnancy; history of immune suppressive medication for more than 7 days.

In our prospective cohort study of MSC transplantation in T1D (ChiCTR2100045434), fourteen participants with available peripheral blood mononuclear cells (PBMC) samples were included in this study to analyze the change of plasmablasts during immunotherapy. Details about the MSC therapy were described as previously reported (Lu et al. 2021). Briefly, MSCs were isolated from Wharton’s Jelly of umbilical cord using the tissue explant method in GMP-certified facilities and underwent a variety of qualification tests. Patients were given 1 × 10⁶ cells/kg as one single intravenous infusion and were followed up after 3 months. Responders were defined as patients with a
10% increase from baseline in the level of fasting and/or postprandial C-peptide.

**Laboratory test**

Standard-meal tolerance test was performed for beta cell function evaluation. After a 10 h overnight fast, each participant received steamed bread with 2.5 g/kg for child and 100 g (containing 75 g carbohydrates) for adult. The levels of plasma glucose and C-peptide before and 2 h after food stimulation were analyzed. HbA1c levels were recorded. GADA, IA2A, and insulin antibodies (IAA) were detected by ELISA; and islet cell antibodies (ICA) was detected by indirect immunofluorescence (all from Oumeng, Beijing, China).

**Flow cytometry**

Human PBMCs were isolated using a BD Mononuclear Cell Preparation Tube according to manufacturer’s instruction. Samples were stained with fluorochrome-conjugant antibodies specific for various cell markers (Additional file 1: Table S1). Fixable Viability Stain 780 was used to discriminate viable cells. Data were collected with an LSRFortessa flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). According to the process of differentiation after antigen stimulation, B cell subsets were identified as: naïve (CD19+IgD+CD27-), unswitched memory (CD19+IgD+CD27-), CD38- switched memory (CD19+IgD-CD27+CD38-), CD38+ switched memory (CD19+IgD-CD27+CD38+), and plasmablasts (CD19+IgD-CD27+CD38hi). The gating strategy is shown in Fig. 1A.

For mouse samples, cells prepared from spleens and lymph nodes were stained with anti-CD138, anti-CD44, anti-CD3e, anti-CD4, and anti-CD8. Plasmablast in mice was characterized by dual staining of CD138 and CD44 (Matsumoto et al. 2014) (Additional file 1: Fig. S1). For intracellular staining, cells were incubated with Leukocyte Activation Cocktail with BD GolgiPlug for 4–6 h and then processed with Fixation/Permeabilization Solution Kit and stained for IFN-γ, TNF-α (BioLegend), granzyme B (eBiosciences), and perforin (eBiosciences) (both from San Diego, CA, USA). Cells were analyzed or sorted with a FACSARia III cell sorter (BD Biosciences). Reagents were purchased from BD Biosciences unless otherwise indicated. Data were analyzed with FlowJo version 10.0 software (Tree Star, Ashland, OR, USA).

**Mice**

Female NOD/ShiLtJ mice and NOD/SCID mice (NOD background, impaired T and B lymphocyte development, deficient natural killer cell function) were obtained from Model Animal Research Center of Nanjing University (Nanjing, China) and housed in a specific-pathogen-free environment (12-h light/dark cycle) with food and water ad libitum. The NOD/ShiLtJ mouse is a model of T1D. NOD/SCID mice were used for adoptive transfer experiments.

**Adoptive transfer**

Plasmablasts and CD3+ T cells were purified (purity > 95%) from spleens and pancreatic lymph nodes (PLNs) from NOD mice (≥ 16-week-old) by FACSARia III. NOD/SCID mice (6-week-old) were injected intravenously with 2 × 10⁶ T cells, 3–5 × 10⁶ plasmablasts, or with a mixture of 2 × 10⁶ T cells and 3–5 × 10⁵ plasmablasts. Controls were treated with PBS. Glucose levels were monitored at least twice weekly using a FreeStyle Blood Glucose Monitoring System (Abbott Diabetes Care Ltd., USA). Diabetes were defined as two consecutive readings ≥ 13.9 mmol/L (250 mg/dL) (Tan et al. 2018; Zhang et al. 2020).

**Histological analysis**

Pancreas were harvest into 4% parafomaldehyde and embedded in paraffin. Tissue Sections (3 μm) were stained with H&E (Servicebio, Wuhan, China) or processed for staining for insulin (GB11334, Servicebio). Insulitis was scored on the basis of islet infiltration with the following grades: grade 0, no insulitis or peri-insulitis; grade 1, insulitis involving < 25% islet; grade 2, insulitis involving 25–50% islet; grade 3, insulitis involving 50–75% islet, and grade 4, insulitis involving > 75% and/
Fig. 1 (See legend on previous page.)
or complete mouse islet infiltration (Akazawa et al. 2015). More than 100 islets were scored in each group. Images were taken using Pannoramic MIDI (3DHISTECH Ltd., Budapest, Hungary).

Immune cells infiltrating into the islets were detected by immunofluorescence. Tissue sections were processed for triple-staining with anti-CD138 (ab34164, Abcam, Cambridge, UK), anti-insulin (83506S), and anti-CD4 (GB13121) or anti-CD8 (GB13429) (all from Servicebio) after EDTA antigen retrieval. The cell nuclei were visualized with DAPI (G1012, Servicebio). Images were captured by an ECLIPSE C1 Microscopy and a DS-U3 digital camera (both from Nikon, Japan).

Co-culture of mouse islets with immune cells
Islets were isolated from 4-week-old NOD mice according to published protocols (Han et al. 2001; Bleich et al. 1999). Briefly, 1 mL cold Hank’s balanced salt solution containing type XI collagenase (1 mg/mL, sigma) was infused into the bile duct via catheter. The inflated pancreas was removed, minced, and digested in a shaker-type water bath at 37 °C. Islets were picked by hand under a microscope and were cultured together in RPMI 1640 medium (glucose: 11.1 mmol/L) containing 10% FBS, 100 units/mL penicillin, and 100 mg/mL streptomycin at 37 °C in a humidified 5% CO₂ atmosphere overnight.

Islets were then cultured in the 96-well round bottom plate (20–30/well) with mIL-2 (10 ng/mL) under conditions: (1) islets alone (control group); (2) with CD4⁺ T cells (2 x 10⁴/well); (3) with plasmablasts (1 x 10⁵/well); (4) with CD4⁺ T cells (2 x 10⁵/well) and plasmablasts (1 x 10⁵/well). CD4⁺ T cells and plasmablasts were sorted from spleens and PLNs of 16-week-old NOD mice. For blocking experiments, plasmablasts were pretreated with neutralizing anti-MHC class II mAb (2.5ug/mL, eBiosciences) or IgG isotype control antibody (2.5ug/mL, eBiosciences) for 1 h before cocultured with islets. After 4 days, supernatants were analyzed with a Luminex assay (LXSAMS, R&D systems) following the manufacturer’s protocol. Islets were collected for apoptosis analysis using PE Annexin V Apoptosis Detection Kit I (BD Bioscience).

Statistics
SPSS version 23.0 (IBM Corporation, Chicago, IL, USA) and GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA) were used for statistical analyses. Student’s t test (for normally distributed data) or Mann–Whitney U test (for skewed data) was used for comparisons between two groups, whereas one-way ANOVA (for normally distributed data) or Kruskal–Wallis test (for skewed data) followed by post hoc comparisons was used for three or more groups. Differences in categorical variables were determined by the χ² analysis or Fisher exact test. Correlations were performed using Pearson or Spearman correlation analysis. Diabetes incidence data were plotted as Kaplan–Meier curves and analyzed using the log-rank test. Two-tailed P < 0.05 was considered statistically significant.

Results
Circulating plasmablast frequency is increased in patients with new-onset T1D and associated with GADA
We recruited patients with new-onset T1D (n = 36), long-term T1D (n = 20), type 2 diabetes (n = 22), and healthy subjects (n = 26). Table 1 summarizes the features of the subjects in each group. There was no difference in age, gender, and BMI between the control, new-onset T1D, and long-term T1D groups. We analyzed B cells using flow cytometry and characterized the major altered B cell subpopulation in peripheral blood based on the differentiation states. The frequencies of total B cells (CD19⁺) were obviously increased in the new-onset T1D, long-term T1D, as well as type 2 diabetes groups (Fig. 1A and B). Furthermore, no significant difference was observed in the frequencies of CD38⁺ switched memory, CD38⁻ switched memory, and unswitched memory B cells in patients with new-onset T1D when compared with the controls and the type 2 diabetes group, while the proportion of naïve B cells was decreased in the new-onset T1D group relative to the controls (Fig. 1C to F). The most notable difference was observed in the plasmablast subset which was significantly increased in patients with new-onset T1D compared with the controls; however, patients with long-term T1D and type 2 diabetes showed no obvious change in the proportion and the number of plasmablasts (Fig. 1G and H).

Further, we examined alterations of plasmablasts in T1D with heterogeneous traits. Patients with new-onset T1D showed increased numbers of plasmablasts compared with their age-matched controls in both juveniles and adults (Fig. 1I). Moreover, plasmablast number was increased in patients complicated by diabetes ketoacidosis or ketoacidosis at onset, but not in those without this emergency (Fig. 1J). Additionally, we analyzed the number of plasmablasts in patients with multiple islet autoantibody positive (Fig. 1K). The significant elevation of plasmablasts was observed in patients who were positive for GADA (Fig. 1L) but not in those with IA2A, ICA, or IAA positive (Fig. 1M to O). There was no significant difference in plasmablast number in patients with different numbers of autoantibodies (Fig. 1P).
The increase of circulating plasmablasts correlates with the deterioration of beta cell function in T1D

To explore the potential role of increased plasmablasts in beta cell destruction, we analyzed the relationship between plasmablast number and beta cell function in patients with new-onset T1D. Meaningfully, the number of plasmablasts was negatively associated with fasting C-peptide \( r = -0.426, P = 0.011 \), as well as 2 h postprandial C-peptide \( r = -0.411, P = 0.020 \) in patients with new-onset T1D (Fig. 2A and B).

After verifying their eligibility as well as informed consent, 14 patients with new-onset T1D received MSC transplantation. Three months after transplantation, the level of HbA1c was significantly decreased (Fig. 2C, \( P < 0.01 \)). The responders (6/14) displayed reduced plasmablast numbers after MSC transplantation, while the non-responders showed inconsistent changes of plasmablasts (Fig. 2D and E). Importantly, both the change of fasting C-peptide \( r = -0.651, P = 0.012 \) and 2 h postprandial C-peptide \( r = -0.709, P = 0.005 \) were negatively correlated with the altered number of circulating plasmablasts (Fig. 2F and G). Taken together, these results indicate a close relationship between the increase of plasmablasts and the deterioration of beta cell function.

Circulating plasmablasts in T1D retain the feature of antigen presentation

B cells have been previously reported to present beta cell-specific antigens and activate diabetogenic T cells (Smith et al. 2017). As a differentiated subset of B cells, plasmablasts are well known for their antibody secretion capacity. Interestingly, by analyzing the expression of HLA-II, CD86, CD80, and CD40 on circulating B cell subsets (Fig. 3A to E), we found that about 80% of plasmablasts retained HLA-II expression (Fig. 3B), and CD86 expression was much higher on plasmablasts than naive B cells (Fig. 3C). Further, compared with control subjects, patients with new-onset T1D displayed significantly higher proportions of HLA-II+ and CD86+ plasmablasts among B cells (Fig. 3F and G), but no difference in the proportion of plasmablasts

### Table 1 Characteristics of participants

|                         | CON (n = 26) | NO-T1D (n = 36) | LT-T1D (n = 20) | T2D (n = 22) | P value |
|-------------------------|-------------|----------------|----------------|-------------|---------|
| Gender, Men (n)         |             |                |                |             |         |
| Age (years)             | 22.2 ± 9.3  | 26.1 ± 14.2    | 27.9 ± 15.3    | 47.3 ± 12.2 \( ^{abc} \) | < 0.001 |
| < 18 years, n (%)       | 10 (38)     | 12 (33)        | 6 (30)         | 0 (0)       |         |
| ≥ 18 years, n (%)       | 16 (62)     | 24 (67)        | 14 (70)        | 22 (100)    |         |
| Onset-age (years)       | /           | 26.1 ± 14.3    | 24.0 ± 15.6    | 47.1 ± 12.8 \( ^{bc} \) | < 0.001 |
| Duration (months)       | /           | 20.2 ± 1      | 45.8 ± 23.5    | 1.3 ± 1.3   | < 0.001 |
| BMII (kg/m²)            | 20.8 ± 2.5  | 19.5 ± 3.0     | 20.6 ± 3.3     | 24.0 ± 2.5 \( ^{bc} \) | < 0.001 |
| DK or DKA (%)           | 0.0         | 75.0           | 55.0           | 9.1         | < 0.001 |
| Family History of Diabetes (%) | 30.8      | 25.0           | 15.0           | 54.5        | 0.033   |
| HbA1c (mmol/mol)        | 34 ± 3.3    | 84 ± 31.7      | 65 ± 26.2      | 96 ± 31.7   |         |
| HbA1c (%)               | 5.3 ± 0.3   | 9.8 ± 2.9 \( ^{a} \) | 8.1 ± 2.4 \( ^{a} \) | 10.9 ± 2.9 \( ^{bc} \) | < 0.001 |
| FPG (mmol/l)            | 4.3 ± 0.5   | 7.4 ± 2.8 \( ^{a} \) | 10.1 ± 4.8 \( ^{ab} \) | 9.5 ± 3.4 \( ^{ab} \) | < 0.001 |
| 2hPG (mmol/l)           | 4.5 ± 1.3   | 13.5 ± 4.68    | 13.3 ± 3.6 \( ^{a} \) | 15.8 ± 3.6 \( ^{a} \) | < 0.001 |
| FCP (pmol/l)            | 558.4 (489.2, 719.0) | 226.0 (141.4, 323.2) \( ^{a} \) | 32.3 (9.8, 242.3) \( ^{a} \) | 520.4 (348.5, 789.1) \( ^{bc} \) | < 0.001 |
| 2hCP (pmol/l)           | 1717 (1321.0, 2261.0) | 425.5 (243.2, 795.8) \( ^{a} \) | 82.9 (16.5, 387.0) \( ^{a} \) | 964.9 (747.6, 1782.0) \( ^{bc} \) | < 0.001 |
| IAA+                    | 0           | 2             | 3             | 0           |         |
| ICA+                    | 0           | 22            | 5             | 0           |         |
| GADA+                   | 0           | 34            | 13            | 0           |         |
| IA2A+                   | 0           | 24            | 8             | 0           |         |
| No. of autoantibodies   |             |                |                |             |         |
| 4                       | 1           | 1             |               |             |         |
| 3                       | 15          | 1             |               |             |         |
| 2                       | 13          | 8             |               |             |         |
| 1                       | 7           | 5             |               |             |         |

Data are n, %, mean ± SD, and median (25th–75th percentile). /, not appropriate. \( ^{a} P < 0.05 \) vs CON; \( ^{b} P < 0.05 \) vs NO-T1D; \( ^{c} P < 0.05 \) vs LT-T1D; NO-T1D, new-onset T1D; LT-T1D, long-term T1D; T2D, type 2 diabetes; FPG, fasting plasma glucose; 2hPG, 2 h postprandial plasma glucose; FCP, fasting C-peptide; 2hCP, 2 h postprandial C-peptide; DK, diabetic ketosis; DKA, diabetic ketoacidosis
expressing CD80$^+$ or CD40$^+$ (Additional file 1: Fig. S2). Additionally, the CD86 expression on plasmablasts negatively correlated with fasting C-peptide ($r = -0.541$, $P = 0.009$) and 2 h postprandial C-peptide ($r = -0.473$, $P = 0.047$) (Fig. 3H), and positively correlated with IFN-$\gamma^+$CD4$^+$ T cell counts ($r = 0.492$, $P = 0.017$) in new-onset T1D subjects, whereas not with that of the overall CD4$^+$ T cells (Fig. 3I). These results suggest plasmablasts retain the antigen-presenting feature which was closely associated with the development of T1D.

Plasmablasts are increased in the spleen, PLNs, and islets with T1D progression in NOD mice

To figure out the expansion process of plasmablasts during the natural history of T1D, we measured plasmablasts in the spleen, PLNs, and islets from NOD mice at 4, 8, 12, and 16 weeks of age. Plasmablasts were dramatically increased in the spleens of NOD mice at 8, 12, and 16 weeks of age compared with 4-week-old mice (Fig. 4A and B). Similarly, CD4$^+$ and CD8$^+$ T cell subsets showed a trend toward increase during disease progression, with
Fig. 3  Plasmablasts in T1D retain the antigen-presenting feature. A Representative histograms of HLA-II, CD86, CD80, and CD40 expression on B cell subsets from patients with new-onset T1D. B–E The analyses of the HLA-II, CD86, CD80, and CD40 expression on B cell subsets. Data indicate mean ± SEM. Difference between groups were assessed by One-way ANOVA followed by Dunnett’s multiple comparisons test. ** P < 0.01 compared with naïve B cells. F–G Comparison of the HLA-II+ and CD86+ plasmablast frequencies in B cell compartment between control subjects and patients with new-onset T1D. Data indicate mean ± SEM. Independent t test, * P < 0.05. H Association between CD86 expression and FCP and 2hCP in patients with new-onset T1D. I Association between CD86 expression on plasmablasts and IFN-γ+CD4+ T cells in patients with new-onset T1D. Correlation was assessed by Pearson analysis. FCP, plasma fasting C-peptide; 2hCP, plasma 2-h postprandial C-peptide.
a significant increase of IFN-γ⁺CD4⁺ T cells in an age-dependent manner (Fig. 4C to E). Concordantly, the frequency of plasmablasts was positively associated with that of IFN-γ⁺CD4⁺ T cells (Fig. 4F).

The PLN is a critical site for the presentation of islet-associated autoantigens to self-reactive T cells. We found that plasmablasts were increased in the PLNs of NOD mice at 8, 12, and 16 weeks of age compared with 4-week-old mice (Fig. 4G and H). Islets from 4-week-old NOD mice displayed well-preserved islet structures with abundant insulin staining, while as the disease progressed, islets exhibited substantial lymphocyte infiltration in 16-week-old NOD mice (Fig. 4I). Immunofluorescence analysis revealed significantly more plasmablasts infiltrating into the islets of NOD mice at 16 weeks compared with those at 4 weeks of age and co-localized with CD4⁺ and CD8⁺ T cells around islets (Fig. 4J and K and Additional file 1: Fig. S6). These results indicate the abnormal increase and islet-infiltration of plasmablasts along with T cells are associated with T1D progression.

Adoptive transfer of plasmablasts promote the onset of T1D in NOD/SCID mice

To further clarify the causative role of plasmablasts in T1D development, we adoptively transferred T cells (T group, n = 11), plasmablasts (PB group, n = 6), or plasmablasts combined with T cells (PB + T group, n = 11) into 6-week-old NOD/SCID mice (euglycemia), respectively. NOD/SCID mice that received PBS injection were taken as controls (CON group, n = 7) (Fig. 5A). One month after transfer, recipient mice in PB + T group showed significantly accumulated plasmablasts in the spleens, PLNs, and islets, while recipients in other groups did not (Fig. 5B and C and Additional file 1: Fig. S3 and Fig. S7).

Meaningfully, mice in the PB + T group developed diabetes faster than those in the T group (Fig. 5D). After 90 days, 45.5% (5/11) of mice in the PB + T group and 9.1% (1/11) of mice in the T group developed diabetes respectively, whereas mice in the PB group and CON group remained normoglycemia (Fig. 5E P = 0.02). Histological analysis of pancreatic sections showed that normal islet architecture was lost in recipient mice in the PB + T group, which was replaced by a large number of immune cell infiltration (Fig. 5F). Most islets in other groups were free of insulitis or with minimal infiltration in the form of peri-insulitis. Recipient mice in the PB + T group showed the highest insulitis score among the four groups (Fig. 5G, P < 0.001). These findings indicate that plasmablasts may play a role in accelerating the T cell-mediated T1D development.

Further, we examined the activation and intracellular cytokines of T cells in the recipient mice. The total number of CD4⁺ T cells in the spleens of PB + T group and T group were comparable, but significantly more CD4⁺ T cells were observed in the PLNs of PB + T group than T group (Fig. 6A). Additionally, CD4⁺ T cells from mice in PB + T group showed a higher frequency of activated CD69⁺ population in the PLNs, as well as higher expressions of activation markers of CD25 and CD69 in the spleen (Fig. 6B and C). Proinflammatory cytokines of IFN-γ and TNF-α were highly expressed by CD4⁺ T cells in the PLNs of the PB + T group relative to the T group (Fig. 6D). However, neither the proliferation nor the activation of CD8⁺ T cells in the spleens or PLNs showed any difference between PB + T group and T group (Additional file 1: Fig. S4A to D). Together, these data suggest that the promotion of diabetes progress by plasmablasts may be associated with the enhanced activation and pro-inflammatory response of CD4⁺ T cells.

Plasmablasts promote T cell-mediated beta cell apoptosis through antigen presentation

To characterize mechanisms underlying the synergistic response between plasmablasts and CD4⁺ T cells during immune destruction of islets, we established an in vitro co-culture system of islets with immune cells (Fig. 6E). Co-culture of plasmablasts combined with CD4⁺ T cells resulted in a significantly increased beta cell apoptosis relative to the control group, whereas no difference was observed in those co-cultured with CD4⁺ T cells or plasmablasts alone (Fig. 6F). Further, the supernatant
Fig. 4 (See legend on previous page.)
from the co-culture of islets together with plasmablasts and CD4+ T cells contained much higher levels of IFN-γ, TNF-α, and granzyme B compared with other culture conditions (Fig. 6G to I). These results indicate that plasmablasts promote islet beta cell destruction by facilitating the proinflammatory response of CD4+ T cells.

We next investigated whether plasmablasts induced the proinflammatory CD4+ T cells through antigen presentation. After pretreatment with neutralizing anti-MHC class II mAb, the amounts of proinflammatory cytokines were obviously reduced (Fig. 6G to I). Consistently, the addition of anti-MHC II mAb resulted in a significant attenuation in the cytotoxic effect of co-cultured plasmablasts and CD4+ T cells on islet beta cells (Fig. 6F). Therefore, our findings suggest that plasmablasts activate the diabetogenic CD4+ T cells via presenting islet autoantigens, resulting in the exacerbation of beta cell destruction.

Discussion

Increasing evidence suggests a vital role for B cells participating in T1D progression. However, altered B cell subpopulations and the mechanisms by which contribute to T1D pathogenesis remain elusive. The present study reveals major alterations in the peripheral B cell compartment in patients with T1D. Plasmablasts are specifically increased in patients with new-onset T1D and correlated with the deterioration of beta cell function. Further, we provide evidence for a role of plasmablasts in aggravating insulinitis and promoting disease onset, yet depending on a synergistic effect with T cells. The mechanism underlying plasmablast-promoted beta cell destruction is at least partially through autoantigen presentation to CD4+ T cells.

Studies attempting to characterize T1D-relevant alteration in the B cell compartment showed inconsistent results. Similar to our finding, Parackova et al. reported a skewed peripheral development of B cells in T1D younger than 20 years old, with a shift towards plasmablasts and a decrease in the transitional B cells (Parackova et al. 2017). But others did not find any disturbance in the peripheral B cell compartment (Hanley et al. 2017; Thompson et al. 2014; Viisanen et al. 2017). The discrepancy may result from variations in study cohorts, cell markers for detection, and measuring techniques. In our study, plasmablasts increased in individuals with new-onset T1D but did not in those with longer duration, indicating that plasmablasts may participate more in the onset of the disease. Besides, participants with relatively larger sample size and with different T1D endotypes were recruited, which implied that plasmablast expansion correlated to the hyperglycemic crisis at diagnosis and the positive islet autoantibody of GADA, indicating an involvement of plasmablasts in islet autoimmunity.

Increased plasmablasts in T1D may either play a role in beta cell destruction or serve as a biomarker of disease status. The former role is supported by both our observational analyses in the new-onset T1D and prospective analysis in the MSC-intervention cohort which showed a decreased number of plasmablasts along with preserved beta cell function. Therefore, plasmablasts are probably part of the imbalanced immune network promoting beta cell destruction. Besides their pathological role in the autoimmune response, the increase of circulating plasmablasts may serve as an indicator for the development of T1D, as supported by their potential to be a biomarker of disease activity in other autoimmune disorders (Banchereau et al. 2016; Pozdzik et al. 2016). Thus, the sensitivity or specificity of circulating plasmablast for evaluation of T1D trajectory may deserve further cohort studies.

To verify our findings in humans, we investigated the role of plasmablasts during the natural disease course in NOD mice. As insulinitis progressed, plasmablasts were increased in spleens and concomitantly accumulated in target tissues of PLNs and islets. In agreement with our results, previous studies reported that B cells infiltrating the islets of NOD mice contained a high proportion of plasmablast- or plasma cell-like subpopulation (Serreze et al. 2011; Boldison et al. 2019). These studies further pointed out a potential relationship between the infiltration of this subpopulation and the limited efficiency of B cell-targeted therapy in preventing or reversing T1D (Serreze et al. 2011; Boldison et al. 2019). The authors used an anti-CD20 antibody to deplete B cells in NOD mice and found that plasmablast-like cells repopulated pancreatic islets after treatment; moreover, these cells with a plasma cell-like phenotype were probably resistant
Fig. 5 (See legend on previous page.)
Plasmablasts promote T cell-mediated beta cell apoptosis through antigen presentation. 

A. Comparison of CD4+ T cell numbers in the spleens and PLNs between PB+T group and T group. 

B. – C. Comparison of activated CD4+ T cells expressing CD25 or CD69 in the PLNs (B) and spleens (C) between PB+T group and T group. 

D. Comparison of IFN-γ+CD4+ T cells and TNF-α+CD4+ T cells in the PLNs between PB+T group and T group. Data indicated mean±SD. Difference were analyzed by Independent t test. * P<0.05, ** P<0.01. ND indicated not determined. 

E. Schematic diagram of the co-culture experiment as described in the methods. 

F. Apoptosis of islet cells in the indicated conditions. 

G. – I. Levels of IFN-γ (G), TNF-α (H), and granzyme B (I) in the supernatants of the indicated conditions. Data indicated mean±SD. Difference were analyzed by One-way ANOVA followed by Bonferroni’s multiple comparisons test. * P<0.05, ** P<0.01. Data indicated mean±SD. One-way ANOVA followed by Tukey’s multiple comparisons test. * P<0.05, ** P<0.01.
to anti-CD20. Thus, the recruitment of plasmablasts in islets probably exert a pathogenic role in beta cell destruction.

We next provided evidence for the potential role of plasmablasts in T1D development and revealed their pathological effect via interaction with T cells. In our clinical samples of new-onset T1D, a correlation between the activation of plasmablasts and CD4+ T cells was observed. Consistently, during the natural progression of insulitis in NOD mice, both the number and the activation of CD4+ T cells were increased in parallel with plasmablast expansion, indicating that there may be an interaction between plasmablasts and CD4+ T cells. Such a potential interaction and its effect on islets were demonstrated in an in vitro co-culture system, which showed that co-culture of islets with a mixture of plasmablasts and CD4+ T cells induced more severe beta cell apoptosis than co-culture with each of the two alone. As a further indication in adoptive transfer assays, co-transfer of plasmablasts and T cells, rather than plasmablasts alone, accelerated the disease onset in NOD/SCID mice, supporting that the pathological effect of plasmablasts is T cell-dependent. Therefore, there is likely to be a synergistic effect between plasmablasts and T cells in T1D pathogenesis.

Previous studies have elucidated the biological characteristics of plasmablasts, including producing protective and/or pathogenic antibodies, secreting cytokines, and in some conditions expressing antigen-presenting molecules as well (Nutt et al. 2015; Tiburzy et al. 2014). In T1D, plasmablasts are traditionally considered as antibody-secreting cells and mainly involved in producing the hallmarks of T1D. But their pathogenic role in mediating autoimmune destruction of islets remains unraveled. In our study, the phenotype and the function of plasmablasts were characterized as the following: (1) abundant expression of antigen-presenting proteins (HLA-II and CD86) with a negative association between CD86 expression and beta cell function; (2) association of increased plasmablasts and beta cell damage during the progression of T1D in both patients and mice; (3) synergistic effect of plasmablasts and T cells in accelerating T1D onset and in promoting beta cell apoptosis. Therefore, our findings addressed the pathogenic function of plasmablasts other than producing autoantibodies. Plasmablasts may directly activate diabetogenic T cells via presenting beta cell autoantigens, which in turn mediates beta cell damage.

Although the antigen-presentation function of antibody-secreting cells was previously reported in a physiological manner, our study firstly clarified the pathological contribution of plasmablasts in islet autoimmunity. A previous study reported plasma cells, a terminally differentiated subset similar to plasmablasts, expressed molecules for antigen presentation and pointed out their physiological function in preventing immune overreaction (Pelletier et al. 2010). In our co-culture system of islets with CD4+ T cells, however, plasmablasts facilitate the T cell reactions against beta cells. Notably, the administration of MHC-II blocking antibodies attenuated the beta cell apoptosis and production of proinflammatory cytokines by CD4+ T cells. Therefore, these data further confirm the antigen-presenting process of plasmablasts. Of note, the TNF-α secretion increased and the apoptosis of beta cells were slightly induced when plasmablasts alone co-cultured with islets (Fig. 6F and H). It needs further study whether plasmablasts affect the apoptosis of islet beta cells in other ways independent of T cells, such as producing inflammatory cytokines or pathogenic autoantibodies.

There are several limitations. Firstly, this study lacks investigation into other mechanisms by which plasmablasts contribute to T1D progression. Plasmablasts have been shown to express IL-17, IL-10, TGF-β, and function as cellular modulators in infection or autoimmune diseases (Matsumoto et al. 2014; Tiburzy et al. 2014; Fournier et al. 2012; Bermejo et al. 2013). Whether plasmablasts promote islet inflammation through dysregulated production of cytokines is worth further exploration. Secondly, the specificity of plasmablasts was not detected in this study. Identifying islet antigen-specific plasmablasts will help understand the pathogenesis of T1D and improve targeted therapy. Thirdly, there are discrepancies between the mice model and human disease. In patients with T1D, the number of infiltrating cells in islets is small or modest, while a massive lymphocyte infiltration is observed in the NOD mice (Morgan and Richardson 2018). The involvement of plasmablasts in islet destruction should be verified in patients with recent-onset T1D in the future.

Conclusions
This study suggests a role for plasmablasts in driving effector T cell response against beta cells and promoting the development of T1D. These findings indicates that targeting plasmablasts may offer new strategies for inhibiting T cell activation and limiting islet autoimmunity. Moreover, detection of circulating plasmablasts might provide a new indicator for assessing islet autoimmunity and the progression of T1D.

Abbreviations
2hCP: 2-Hour postprandial C-peptide; FCP: Fasting C-peptide; DK: Diabetic ketosis; DKA: Diabetic ketoacidosis; GADA: Glutamate decarboxylase antibody; IA2A: Tyrosine phosphatase antibody; IAA: Insulin antibodies; ICA: Islet cell antibodies; MSC: Mesenchymal stromal cell; NOD mice: Non-obese diabetic mice; PLN: Pancreatic lymph node; PBMC: Peripheral blood mononuclear cell; T1D: Type 1 diabetes; T2D: Type 2 diabetes.
Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s10020-022-00447-y.

Additional file 1: Table S1. Reagents used for flow cytometry: Figure S1. Flow cytometry gating strategy in mice. Figure S2. Features of plasmablasts in patients with new-onset T1D. Figure S3. Reconstruction of adoptively transferred cells in the PLNs of recipient mice 4 weeks after transfer. Figure S4. The activation of CD8+ T cells is not influenced by plasmablasts. Figure S5. The number of plasmablasts did not correlate with beta cell function in patients with long-term T1D or T2D. Figure S6. Individual staining of CD138, CD4, CD8, and insulin (related to Fig. 4J). Figure S7. Individual staining of CD138, CD4, CD8, and insulin (related to Fig. 5C). Figure S8. Plasmablasts promote the IFN-γ production by T cells in T1D (answer to the reviewer).

Acknowledgements
We thank all of the participants in this study.

Authors’ contributions
QL, LS, and JL conceived the study, designed and performed the experiments, analyzed and interpreted data, prepared figures and tables. WZ and DQ contributed to the acquisition of clinical samples and the analysis of data. JL and BW participated in the MSC transplantation. WZ, HW, and YL participated in the animal experiments and data analysis. QL and JL draft the manuscript. DZ and YB supervised the study, interpreted the results, and revised the manuscript. All authors read and approved the final manuscript.

Funding
The study was sponsored by grants from the National Key Research and Development Program of China (2017YFC1309605), Nanjing Health Youth Talent (QRX17123) and Jiangsu Provincial Key Medical Discipline (XK201105, ZDXK20160102).

Availability of data and materials
The data used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Drum Tower Hospital Ethics Review Committee (Approval Number: 2019-07-02; SC201600203). All participants and/or their guardians provided written informed consent at recruitment. The study was carried out in accordance with the principles of the Declaration of Helsinki. The animal study was reviewed and approved by Drum Tower Hospital Research Animal Care Committee (Approval number: 2019AE01099).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Endocrinology, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. 2Department of Laboratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. 3Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 4Clinical Stem Cell Center, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. 5Department of Laboratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. 6Department of Laboratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. 7Department of Laboratory Medicine, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.

Received: 19 October 2021 Accepted: 27 January 2022
Published online: 05 February 2022

References
Akazawa S, et al. Haploinsufficiency of interferon regulatory factor 4 strongly protects against autoimmune diabetes in NOD mice. Diabetologia. 2015;58:2606–14.
American Diabetes Association (2020) 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020. Diabetes Care 43: S14–s31.
Banchereau R, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165:551–65.
Barnett R. Type 1 diabetes. Lancet (London, England). 2018;391:195.
Bermieco DA, et al. Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors RORgammat and Ahr that leads to IL-17 production by activated B cells. Nat Immunol. 2013;14:514–22.
Bleich D, et al. Resistance to type 1 diabetes induction in 12-lipoxygeenase knockout mice. J Clin Investig. 1999;103:1431–6.
Bolldon J, Wong FS. Immune and pancreatic beta cell interactions in type 1 diabetes. Trends Endocrinol Metab. 2016;27:856–67.
Bolldon J, et al. Phenotypically distinct anti-insulin B cells repopulate pancreatic islets after anti-CD20 treatment in NOD mice. Diabetologia. 2019;62:2052–65.
Damond N, et al. A map of human Type 1 diabetes progression by imaging mass cytometry. Cell Metab. 2019;29:755–768.e755.
Deng C, et al. Altered peripheral B-lymphocyte subsets in Type 1 diabetes and latent autoimmune diabetes in adults. Diabetes Care. 2016;39:434–40.
Falcone M, Lee J, Patstone G, Yeung B, Sarvetnick N. B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol. 1998;161:1163–8.
Fournier EM, et al. Dual-reactive B cells are autoreactive and highly enriched in the plasmablast and memory B cell subsets of autoimmune mice. J Exp Med. 2012;209:1797–812.
Han X, Sun Y, Scott S, Bleich D. Tissue inhibitor of metalloproteinase-1 prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and beta-cells. Diabetes. 2001;50:1047–55.
Hanley P, et al. Circulating B cells in type 1 diabetics exhibit fewer maturation-associated phenotypes. Clin Immunol (Orlando, Fla). 2017;183:336–43.
Hu CY, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Investig. 2007;117:3857–67.
Kleffel S, et al. Interleukin-10+ regulatory B cells arise within antigen-experienced CD40+ B cells to maintain tolerance to islet autoantigens. Diabetes. 2015;64:158–71.
Lampasona V, Liberati D. Islet autoantibodies. Curr Diab Rep. 2016;16:53.
Leete P, et al. Differential insulitic profiles determine the extent of beta-cell destruction and the age at onset of Type 1 diabetes. Diabetes. 2016;65:1362–9.
Ling Q, et al. Risk of beta-cell autoimmunity presence for progression to type 1 diabetes: a systematic review and meta-analysis. J Autoimmun. 2018;86:9–18.
Lu J, et al. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study. Stem Cell Res Ther. 2021;12:340.
Matsumoto M, et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity. 2014;41:1040–51.
Morgan NG, Richardson SJ. Fifty years of pancreatic islet pathology in human type 1 diabetes: insights gained and progress made. Diabetologia. 2018;61:2499–506.
Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15:160–71.
Parackova Z, et al. Alteration of B cell subsets and the receptor for B cell activating factor (BAFF) in paediatric patients with type 1 diabetes. Immunol Lett. 2017;189:94–100.
Pelletier N, et al. Plasma cells negatively regulate the follicular helper T cell program. Nat Immunol. 2010;11:1110–8.
Pescovitz MD, et al. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care. 2014;37:453–9.
Pescovitz MD, et al. B-lymphocyte depletion with rituximab and beta-cell function: two-year results. Diabetes Care. 2014;37:453–9.
Pozdziech A, et al. Circulating (CD3+CD4+CD20+) B cells in IDDM patients. Diabetes Care. 2003;26:2143–52.
Pozdziech A, et al. Circulating (CD3+CD4+CD20+) B cells in IDDM patients. Diabetes Care. 2003;26:2143–52.
Received: 19 October 2021 Accepted: 27 January 2022
Published online: 05 February 2022

Supporting Information

S1. Flow cytometry gating strategy in mice. S2. Features of plasmablasts in patients with new-onset T1D. S3. Reconstruction of adoptively transferred cells in the PLNs of recipient mice 4 weeks after transfer. S4. The activation of CD8+ T cells is not influenced by plasmablasts. S5. The number of plasmablasts did not correlate with beta cell function in patients with long-term T1D or T2D. S6. Individual staining of CD138, CD4, CD8, and insulin (related to Fig. 4J). S7. Individual staining of CD138, CD4, CD8, and insulin (related to Fig. 5C). S8. Plasmablasts promote the IFN-γ production by T cells in T1D (answer to the reviewer).
Serreze DV, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new “speed congenic” stock of NOD.Ig mu null mice. J Exp Med. 1996;184:2049–53.
Serreze DV, et al. Loss of intra-islet CD20 expression may complicate efficacy of B-cell-directed type 1 diabetes therapies. Diabetes. 2011;60:2914–21.
Smith MJ, et al. Loss of anergic B cells in prediabetic and new-onset type 1 diabetic patients. Diabetes. 2015;64:1703–12.
Smith MJ, Simmons KM, Cambier JC. B cells in type 1 diabetes mellitus and diabetic kidney disease. Nat Rev Nephrol. 2017;13:712–20.
Smith MJ, et al. Silencing of high-affinity insulin-reactive B lymphocytes by anergy and impact of the NOD genetic background in mice. Diabetologia. 2018;61:2621–32.
Tan Q, et al. (2018) Activation-induced cytidine deaminase deficiency accelerates autoimmune diabetes in NOD mice. JCI Insight 3.
Thompson WS, et al. Multi-parametric flow cytometric and genetic investigation of the peripheral B cell compartment in human type 1 diabetes. Clin Exp Immunol. 2014;177:571–85.
Tiburzy B, Kulkarni U, Hauser AE, Abram M, Manz RA. Plasma cells in immunopathology: concepts and therapeutic strategies. Semin Immunopathol. 2014;36:277–88.
Viisanen T, et al. Circulating CXCR5+PD-1+ICOS+ follicular T helper cells are increased close to the diagnosis of Type 1 diabetes in children with multiple autoantibodies. Diabetes. 2017;66:437–47.
Wang YJ, et al. Multiplexed in situ imaging mass cytometry analysis of the human endocrine pancreas and immune system in Type 1 diabetes. Cell Metab. 2019;29:769-783.e764.
Yang JHM, et al. Phenotypic analysis of human lymph nodes in subjects with new-onset Type 1 diabetes and healthy individuals by flow cytometry. Front Immunol. 2019;10:23547.
Zhang J, et al. Extracellular HMGB1 exacerbates autoimmune progression and recurrence of type 1 diabetes by impairing regulatory T cell stability. Diabetologia. 2020;63:987–1001.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.